Gut microbial-related metabolite trimethylamine-N-oxide and its precursor L-carnitine are associated with spontaneous preterm birth: a nested case-control study

Xing Chen
Guangxi Medical University https://orcid.org/0000-0002-3143-9556

Ning Huang
Guangxi Province environmental monitoring

Chaoqun Liu
Guangxi Medical University

Yue Chen
Guangxi Medical University First Affiliated Hospital

Lulu Huang
Guangxi Medical University

Xiujuan Zhu
Guangxi Medical University

Dehao Cao
Guangxi Medical University

Jin Wang
guangxi province environmental monitoring

Juan Ye
Guangxi Medical University

Qingzhi Hou
Guangxi Medical University

mujun Li
Guangxi Medical University First Affiliated Hospital

Zengnan Mo
Guangxi Medical University

Xiaobo Yang (yangx@gxmu.edu.cn)

Research

Keywords: Spontaneous preterm birth, gut microbiota, TMAO, L-carnitine, betaine, nested case-control study, metabolism
Abstract

Background: Gut microbiota has been proven to disease susceptibility and may lead to increased risk of preterm birth. To date, the link of gut microbial-related metabolite trimethylamine-N-oxide (TMAO), L-carnitine, and betaine, with spontaneous preterm birth (sPTB) has not been established. This study aimed to investigate the association of TMAO, L-carnitine and betaine, with sPTB risk.

Methods: A nested case-control study was designed including 129 sPTB cases and 258 controls based on Guangxi Birth Cohort Study. TMAO, L-carnitine, and betaine level in maternal serum were determined by liquid chromatography with mass spectrometry. Conditional logistic regression analyses were used to examine the association between maternal serum metabolites and sPTB. Stratified analyses were further conducted according to BMI and preterm prelabor rupture of membranes. Spline analyses were performed to explore the dose-response relationship between the metabolites and sPTB.

Results: Statistically significant association with decreased sPTB risk was observed for the highest L-carnitine (OR: 0.47; 95% CI: 0.23, 0.95). In risk analyses stratified by BMI, similar results were observed in normal weight gravida (BMI: 18.5~23.9 kg/cm²). The significant subtype-specific association with TMAO (OR: 0.43; 95% CI: 0.20, 0.93) and L-carnitine (OR: 0.45; 95% CI: 0.21, 0.97) were observed for preterm labor but not PPROM. Spline regression analysis indicated non-linear associations with TMAO and sPTB risk (P for nonlinearity: 0.057). Significant associations of TMAO with sPTB were observed in normal weight gravida (P = 0.028) and preterm labor subtype (P = 0.025). No statistically significant associations with sPTB risk were observed for betaine (P > 0.05).

Conclusions: TMAO and L-carnitine levels in maternal serum are inversely linked with sPTB risk. Discovery of the association between gut-microbiota initiated TMAO metabolism and sPTB may open new avenues for diagnose and therapy.

Background

Spontaneous preterm birth (sPTB), delivered at less than 37 weeks’ gestation age, remains most common complication in obstetrics and gynecology [1, 2]. sPTB is the leading perinatal morbidity and mortality worldwide [3]. Preterm infants have been verified to face quite complicated issues such as low birth weight, feeding difficult, high quality of neonatal intensive care, and an increased risk of neurodevelopmental impairments, respiratory and gastrointestinal complications in adulthood compared with their term counterparts [3]. Hence, effective prediction of sPTB is useful to allow us to initiate appropriate risk-specific treatment and reduce the risk as far as possible. However, the pathogenesis of sPTB remained elusive [1, 2]. Population and genetic characteristics, individual behaviors (diabetes, smoking, pressure and drinking), environmental exposures, pathological status (hypertension, obesity), and physical markers (cervical length) appeared to low efficiency and limited accuracy to identify sPTB [2, 4, 5]. Biomarkers found in body fluids, such as cytokines (cervical IL-6), genes, proteins (serum C-reactive protein, fetal fibronectin, β-hCG, placental α-microglobulin), nutritional status have been identified as preterm risk factor, but few biomarkers have shown sufficient sensitivity and specificity in clinical application [2].
Recently, gut microbiota metabolites trimethylamine N-oxide (TMAO) has been received increasing attentions. The growing recognition of a contributory role of gut microbiota to health and disease promises that great efforts have devoted to define the cause-effect between gut microbiota and preterm birth [6–9]. Moreover, experimental and clinical studies have demonstration that TMAO synthesized by the intestinal microbiota is involved in the progression of atherosclerosis, cardiovascular disease, type 2 diabetes, vitamin D deficiency, chronic kidney disease, non-alcoholic fatty liver disease [10–12]. Those adverse impacts induced by microbial-related metabolite TMAO may directly affect the physical condition of pregnant women and birth outcomes [13, 14]. Meanwhile, TMAO is a gut microbiota-dependent metabolite of L-carnitine [15]. L-carnitine participates in energy metabolism and is essential to fetal growth and organ development [16]. L-carnitine, similar to glycine betaine (betaine) in structure, belongs to the “betaines” group [17, 18]. Betaine serves as an osmolyte to protect cell and protein from environmental stress, and a methyl group donor to homocysteine for synthesis of methionine [19, 20]. Betaine insufficiency is attributable to the high risk factors of the metabolic abnormalities, obesity, diabetes, and vascular disease [18].

Despite gut-microbiota dependent L-carnitine metabolism has been linked to maternal health and fetus developments, the association of TMAO and its precursor (L-carnitine, betaine), with sPTB risk has not yet been reported. Herein, this study conducted a nested case-control study to investigate the association of TMAO, L-carnitine and betaine levels in maternal serum, with sPTB risk in a large Chinese population.

**Materials And Methods**

**Study Design and Population**

Our nested case-control study was embedded in the Guangxi Birth Cohort Study (GBXCS), an ongoing multicenter prospective cohort study in Guangxi, South China, which aims to investigate pregnancy outcome and offspring short- and long-term health consequences of hereditary, environmental and lifestyles factors in the fast-paced society. The baseline design of the GBCS has been previously reported [21]. Flow chart of the study population was shown in Figure 1. 6,203 volunteers had been recruited at the baseline from July to September in 2015 in seven maternal & child health hospitals in Guangxi when they joined prenatal examination.

In 2016, after first follow-up survey, 5,541 (89.33%) mother-infant pairs had been observed. 206 pregnant women (delivery week < 37 weeks) were selected excluding abortion, stillbirth and birth defects, multiple pregnancies, medically premature delivery, full-term low birth weight and Macrosomia. To minimize the effect of the erratic menstrual cycle on gestation age, we carried out 129 participants delivers at < 36 weeks’ gestation age as cases in this work. 258 term deliveries (delivery week ≥ 37 weeks) were selected randomly according to maternal age, enrollment hospital, enrollment gestational age at baseline blood draw and infant gender as controls. This study was approved by Medical Ethics Committee of First Affiliated Hospital of Guangxi Medical University (ID: 2015(028)). All patients consented to participate in the research, and written informed consent was obtained from each patient.

**Analytic measurements**
The standards consisted of Trimethylamine oxide (TMAO, Sigma–Aldrich, USA), betaine (UPS Reference Standard, USA), and L-carnitine (UPS Reference Standard, USA). d9-TMAO, L-carnitine-d9, and d11-betaine were obtained from Cambridge Isotop Laboratories, Inc. (USA) and used as internal standards. Serum were collected and stored at -80 °C until analysis. Frozen serum samples were thawed and centrifuged at 4 °C for 5 min. Serum concentrations of TMAO, L-carnitine and betaine were quantified using stable isotope internal standards method on an Agilent 6460 triple quadrupole mass spectrometer in positive multiple reaction monitoring (MRM) mode according to the literature method with slight modifications [15, 22]. Agilent ZORBAX HILIC plus column (2.1 × 50 mm, 3.5 μm, Agilent, USA) was used. 20 μL plasma was aliquoted into 1.5 mL tubes and mixed with 980 μL protein precipitate solution (methanol/acetonitrile 10: 90) containing internal standards. Proteins in samples were precipitated by vortexing for 1 min, and centrifuged (13,000 rpm for 10 min). Filter the solution through 0.22 cm filters, and keep it at 4 °C. 3 μL supernatant was injected for HPLC-MS analysis. Two solvents were used for gradient elution: (A) 5 mM ammonium acetate, (B) methanol. The flow rate was 0.4 mL/min, and the column temperature was maintained at 25 °C. The blind duplicate samples (N = 20) were interspersed to evaluate quality control. The intraclass correlation coefficients for each metabolite were as follows: TMAO, 0.912; L-carnitine, 0.998; betaine, 0.983.

Statistical Analyses

The baseline characteristics of cases and controls were performed using descriptive analysis. Continuous variables were compared using t-tests and categorical variables compared using chi-square tests. Conditional logistic regression analyses were used to examine the association between maternal serum metabolites tertile concentrations and preterm delivery by calculating odds ratios (ORs) and their 95% confidence intervals (CIs), which were adjusted by maternal age, ethnic, education levels, smoking, and drinking status during pregnancy. Stratified analyses were further conducted according to BMI (< 18.5, 18.5 - 23.9, ≥ 24 kg/m²), and PPROM (yes, no) by using logistic regression. Linear trend P-values were derived by modeling the median value of each tertile as a continuous variable in adjusted models. A spline analysis to explore the dose-response relationship of the selected biomarkers and the risk of sPTB was performed. Knots were placed at the 25th, 50th, and 75th percentiles of the serum TMAO distribution, and the reference value was set at the 25th percentile. Adjustment factors were age, pre-pregnancy BMI (not for BMI stratified model), ethnic, education, smoking, and drinking. SPSS version 22.0 (IBM) and SAS (version 9.4; SAS Institute Inc.) were applied in statistical analysis. Two-sided P < 0.05 was considered as statistical significance.

Results

Baseline characteristics of sPTB cases (n = 129) and controls (n = 258) are shown in Table1. Compared with the controls, the cases involved in a higher BMI (P = 0.02), lower infant weight (P < 0.001) and shorter infant height (P < 0.001). No significant differences were observed in maternal age, ethnic, family income, educational levels, drinking, smoking, gestational age at sample collection, infant gender, history of gravid and parity, and infant gender (all P > 0.05). The sPTB group had a higher percentage of preterm labor (n = 63, 48.8%). As well, the percentage of PPROM was 43.4% (n = 56), and 10 cases were unknown (7.8%). Serum concentrations of TMAO, L-carnitine, and betaine did not differ between cases and controls.
Associations between maternal serum TMAO, L-carnitine and betaine level and sPTB risk are shown in Figure 2. Statistically significant associations with decreased sPTB risk were observed for the highest categories of L-carnitine. Multivariable-adjusted for age, pre-pregnancy BMI, ethnic, education, smoking, and drinking, women in highest tertile of L-carnitine were 53% lower sPTB risk than those in lowest tertile (OR= 0.47; 95% CI: 0.23, 0.95; P_{trend} 0.035). However, no statistically significant associations with sPTB risk were observed for TMAO and betaine (all \( P > 0.05 \)). Spline regression analysis indicated marginally significant non-linear associations with TMAO and sPTB risk (Figure 3A, \( P \) for overall = 0.070, \( P \) for nonlinearity = 0.057), with a sharp decrease in slope for concentrations above 1.63 \( \mu \text{mol/L} \). Other metabolites had no dose-relationship with sPTB (all \( P > 0.05 \)).

In risk analyses stratified by pre-pregnancy BMI (Figure 2B - 2D), statistically significant associations with decreased sPTB risk were observed only for L-carnitine categories in subset with BMI between 18.5 and 23.9 (Figure 2C, OR= 0.46; 95% CI: 0.23, 0.93; \( P_{trend} = 0.030 \)). Of Note, Spline regression analysis indicated significant non-linear association for sPTB risk and TMAO in the same BMI subset (Figure 3B, \( P \) for overall = 0.028, \( P \) for nonlinearity = 0.011). No significant associations with sPTB risk were observe for the other metabolites (all \( P > 0.05 \)).

The associations with serum metabolites through analyses of common sPTB subtypes PPROM and preterm labor were further explored (Figure 2E, 2F). The significant subtype-specific association with decreased TMAO (OR = 0.43; 95% CI: 0.20, 0.93, \( P_{trend} = 0.033 \)) and L-carnitine (OR = 0.45; 95% CI: 0.21, 0.97; \( P_{trend} = 0.041 \)) were observed for preterm labor. A linear relationship of TMAO and sPTB risk was found only for preterm labor cases in the spline analysis (Figure 3C, \( P \) for overall = 0.025, \( P \) for nonlinearity = 0.507). Analyses of the other metabolites did not suggest clear associations with specific sPTB subtypes.

**Discussion**

As far as we know, this is the first study to assess the associations of gut microbial-related metabolite TMAO and its precursor L-carnitine with sPTB risk. A nonlinear association between serum TMAO and sPTB risk were observed. According to pre-pregnancy BMI, the nonlinear association between the serum TMAO and sPTB risk were observed in normal BMI. Meanwhile, preterm birth subtypes appeared to modify the association between serum TMAO and sPTB risk with linear association observed in the preterm labor, but not in PPROM. L-carnitine levels in maternal serum were inversely associated with sPTB. The significant subtype-specific associations with L-carnitine were observed in normal BMI and preterm labor. As such, the association of maternal serum TMAO and L-carnitine with sPTB risk appears to be dependent on BMI and preterm labor availability. Additionally, no correlation was found between betaine and sPTB.

Nutrition metabolism in the context of pregnancy is crucial to maternal health and fetus development from the pre-implantation embryo to infancy [23, 24]. The gut microbiome has been identified to change during gestation [7]. Shiozaki et al. demonstrated that disturbance of intestinal microbiota would result in preterm delivery in a prospective and cross-sectional study [8]. Dahl et al. provided further evidences for the impact of the low gut diversity and low relative abundance of bifidobacterium and streptococcus on sPTB [9]. The
changes of gut microbiome diversity and evenness may alter bioactivation of nutrients and vitamins, normal physiology of host, and at same times, also affect immune system [25–27].

In this study, our data have uncovered increased sPTB risk was observed for the low categories of TMAO and L-carnitine. These findings revealed that the gut-microbiota initiated TMAO metabolism may represent a key factor contributing to sPTB. Gut microbial-related metabolite TMAO depend on the dietary sources from fish or endogenous synthesis from L-carnitine present in eggs, milk and red meat.[15] L-carnitine can be metabolized to TMA by the anaerobic intestinal bacteria, then further oxidized to TMAO [15]. L-carnitine participates in energy metabolism as the transfer of activated long-chain fatty acids into the mitochondrial matrix, regulates coenzyme A (CoA)/acylCoA ratio and maintains energy storage in the form of acetylcarnitine [16, 28]. Maternal plasma carnitine levels on delivery decrease to half of the concentrations in non-pregnant women, comparable to those found in known carnitine deficiency [29]. L-carnitine deficiency has been implicated in the pathogenesis of cardiomyopathy, skeletal weakness, diabetes mellitus, hyperammonaemia, and other disorders [15, 28, 30]. L-carnitine supplementation in pregnancy doses avoids insulin resistance and gestational diabetes mellitus [31]. Because the low activity of the butyrobetaine hydroxylase was to restrict the endogenous synthesis of carnitine in fetal tissue, fetal L-carnitine level mainly depended on the maternal carnitine via transplacental transfer [32, 33]. L-carnitine supplementation in pregnancy is highly demand to pregnant women and their fetuses. Therefore, low TMAO and carnitine status of pregnant women may lead to malnutrition, organ dysfunction, and embryonic development restriction. In addition, TMAO synthesized by the intestinal microbiota has been demonstrated as early predictors of metabolic syndrome, and strong linked with atherosclerosis, type 2 diabetes, vitamin D deficiency and chronic kidney disease [10–12, 34]. The metabolic syndrome induced by TMAO caused increased sPTB risk [13, 14]. Collectively, the nonlinear relationship between TMAO level and sPTB has been uncovered, with a significant positive association for the low level and an inverse association with high TMAO concentration.

In the stratified analysis, the effect of serum TMAO and L-carnitine levels on sPTB depended on the level of pre-pregnancy BMI. The adverse association of serum TMAO and L-carnitine, with sPTB risk became insignificant among the low or High BMI, and PPROM. Schugar et al. found that levels of the TMAO-producing enzyme flavin-containing monoxygenase (FMO3) is linked to obesity [35]. The effect of BMI on FMO3/TMAO metabolism pathway could partially explain the improved predictive ability with BMI stratification. In addition, a growing body of evidence suggests that utero infection and vaginal microorganisms have been causally associated to PPROM [36, 37]. The effect caused by the inflammatory activation on sPTB was much greater than those of TMAO and L-carnitine, which may cover the risk effect of TMAO and L-carnitine on sPTB in PPROM.

In this study, null associations between betaine and sPTB risk were noted. Betaine serves as an osmolyte. The betaine concentration in tissue is much higher than that in serum, while serum betaine is presumably mainly influenced by liver betaine level [18, 38]. Thus, the serum betaine could not reflect the whole level of the pregnant women, which may weaken the effect of serum betaine on sPTB.

Key strengths of this study are that this is the first study to investigate the association of maternal serum TMAO, L-carnitine and betaine, with sPTB risk in humans. Furthermore, in this nested case-control study,
cases and controls were enrolled with comparable age, ethnic, family incomes, education, drinking, smoking, gestational age at sample collection, gravid, parity and infant gender in order to minimize recall bias. Thirdly, to reduce multiple confounding factors, well-established factors (i.e., age, pre-pregnancy BMI, ethnic, education, smoking, and drinking) were included in the analyses. The main limitation of this study is that although cases and controls were recruited with complete matching by gestational age at sample collection, the concentrations of serum TMAO, L-carnitine, and betaine have changes during gestation, one sample collection may not exactly give an accurate representation of the metabolites levels. Secondly, although we have considered some confounding factors in the analyses, there is a potential for residual confounding factors that were not recorded. Thirdly, the sample size might be relatively small, limiting the statistical power to detect associations of stratified analyses. More prospective studies are required to verify the causality between TMAO, L-carnitine and sPTB.

Conclusion

TMAO and L-carnitine were inversely linked with sPTB, while betaine level is not associated with sPTB risk. If possible, these results should be confirmed by large prospective studies in the future. It is worthwhile to make further study of the mechanism of the effect of gut-microbiota initiated L-carnitine/TMA/TMAO metabolism path way on the sPTB. Discovery of a relationship between gut-microbiota initiated nutrition metabolism and sPTB provides opportunities for the development of new diagnostic procedures and therapeutic strategy for sPTB.

Declarations

Acknowledgments

We extremely thank the department of Maternal and Child Health Services of the Guangxi Zhuang Autonomous Region Health and Family Planning Commission.

Ethics approval and consent to participate

The study was reviewed and approved by the Guangxi Medical University Medical Ethics Committee (ID: 2015(028), Approved 16 July 2015). All patients consented to participate in the research, and written informed consent was obtained from each patient.

Consent for publication

All authors have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere.

Availability of data and materials

The data used to support the findings of this study are included within the article or available from the corresponding author upon request.

Conflicts of Interest
The authors declare no conflict of interest.

**Funding**

This study was funded by Guangxi Natural Science Fund for Innovation Research Team (2017GXNSFGA198003), Guangxi science and technology project (GKG1598011-3) and Natural Science Foundation of Guangxi Province (2017GXNSFBA198028).

**Author Contributions**

XBY, ZNM: designed the research protocol; XC, NH, XJZ, DHC, JW, JY: conducted the research; YC and MJL participated in the study conception. XC, NH, CQL, LLH, XJZ, DHC, QZH, XBY: analyzed the data; XC, NH, CQL, XBY: drafted the manuscript; XBY: had primary responsibility for final content. All authors critically revised and approved the final version of the manuscript.

**Author details**

1 Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, Guangxi, China

2 School of Public Health of Guangxi Medical University, Nanning, Guangxi, China

3 Department of Occupational Health and Environmental Health, School of Public Health of Guangxi Medical University, Nanning, Guangxi, China

4 Institute of Urology and Nephrology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

5 Guangxi Province Environmental Monitoring Center, Nanning, Guangxi, China

6 Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

7 Department of Reproductive Center, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

**References**

1. Romero R, Dey SK, Fisher SJ. Preterm labor: One syndrome, many causes. Science. 2014;345:760.
2. Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of preterm birth. Lancet. 2008;371:75-84.
3. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008;371:261-269.
4. Saurel-Cubizolles MJ, Zeitlin J, Lelong N, Papiernik E, Di Renzo GC, Bréart G. Employment, working conditions, and preterm birth: results from the Europop case-control survey. J Epidemiol Community
5. Wanigaratne S, Cole DC, Bassil K, Hyman I, Moineddin R, Urquia ML. The influence of refugee status and secondary migration on preterm birth. J Epidemiol Community Health. 2016;70:622.

6. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920.

7. Smid MC, Ricks NM, Panzer A, McCoy AN, Azcarate-Peril MA, Keku TO, Boggess KA. Maternal gut microbiome biodiversity in pregnancy. Amer J Perinatol. 2018;35:024-030.

8. Shiozaki A, Yoneda S, Yoneda N, Yonezawa R, Matsubayashi T, Seo G, Saito S. Intestinal microbiota is different in women with preterm birth: results from terminal restriction fragment length polymorphism analysis. Plos One. 2014;9:e111374-e111374.

9. Dahl C, Stanislawski M, Iszatt N, Mandal S, Lozupone C, C. Clemente J, Knight R, Stigum H, Eggø M. Gut microbiome of mothers delivering prematurely shows reduced diversity and lower relative abundance of Bifidobacterium and Streptococcus. Plos One. 2017;12:e0184336.

10. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, DuGar B, Feldstein AE, Britt EB, Fu X, Chung Y-M, Wu YP, Schauer P, Smith JD, Allyae H, Tang WHW, DiDonato JA, Lusis AJ, Hazen SL. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472:57.

11. Al-Obaide M, Singh R, Datta P, A Rewers-Felkins K, V Salguero M, Al-Obaidi I, Kottapalli K, Vasylyeva T: Gut microbiota-dependent trimethylamine-N-oxide and serum biomarkers in patients with T2DM and advanced CKD. J Clin Med. 2017;6:86.

12. Tang WHW, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, Li XS, Levison BS, Hazen SL. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circulation Res. 2015;116:448-455.

13. Kramer MS, Kahn SR, Rozen R, Evans R, Platt RW, Chen MF, Goulet L, Séguin L, Dassa C, Lydon J, McNamara H, Dahhou M, Genest J. Vasculopathic and thrombophilic risk factors for spontaneous preterm birth. Int J Epidemiol. 2009;38:715-723.

14. Jiang S, Jiang J, Xu H, Wang S, Liu Z, Li M, Liu H, Zheng S, Wang L, Fei Y, Li XW, Ding YF, Wang ZP, Yu YX. Maternal dyslipidemia during pregnancy may increase the risk of preterm birth: A meta-analysis. Taiwanese J Obstet Gynecol. 2017;56:9-15.

15. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WHW, Bushman FD, Lusis AJ, Hazen SL. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19:576.

16. Rebouche CJ, Seim H. Carnitine metabolism and its regulation in microorganism and mammals. Ann Rev Nutr. 1998;18:39-61.

17. Lever M, Bason L, Leaver C, Hayman CM, Chambers ST. Same-day batch measurement of glycine betaine, carnitine, and other betaines in biological material. Anal Biochem. 1992;205:14-21.

18. Lever M, Slow S. The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem. 2010;43:732-744.
19. Katayama K, Sato T, Arai T, Amao H, Ohta Y, Ozawa T, Kenyon PR, Hickson RE, Tazaki H. Non-targeted analyses of animal plasma: betaine and choline represent the nutritional and metabolic status. J Anim Physiol Anim Nutr. 2013;97:119-125.

20. Craig SA. Betaine in human nutrition. Am J Clin Nutr. 2004;80:539-549.

21. Huang L, Hou Q, Huang Y, Ye J, Huang S, Tian J, Tang R, Liu C, Long Y, Qin X, Wang X, Huang Y, Li M, Yang X, Mo Z. Serum multiple cytokines for the prediction of spontaneous preterm birth in asymptomatic women: A nested case-control study. Cytokine. 2019;117:91-97.

22. Liu J, Zhao M, Zhou J, Liu C, Zheng L, Yin Y. Simultaneous targeted analysis of trimethylamine-N-oxide, choline, betaine, and carnitine by high performance liquid chromatography tandem mass spectrometry. J Chromatography B. 2016;1035:42-48.

23. Zhang Y, Zhou H, Perkins A, Wang Y, Sun J. Maternal dietary nutrient intake and its association with preterm birth: a case-control study in Beijing, China. Nutrients. 2017;9:221.

24. L Carmichael S, Yang W, M Shaw G. Maternal dietary nutrient intake and risk of preterm delivery. Am J Perinatol. 2013;30:579–88.

25. Bäckhed F, K Manchester J, F Semenkovich C, I Gordon J: Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci USA. 2007;104: 979-984.

26. Chung H, Pamp SJ, Hill JA, Surana NK, Edelman SM, Troy EB, Reading NC, Villablanca EJ, Wang S, Mora JR, Umesaki Y, Mathis D, Benoist C, Relman DA, Kasper DL. Gut immune maturation depends on colonization with a host-specific microbiota. Cell. 2012;149:1578-1593.

27. Neufeld MK, Kang N, Bienenstock J, Foster J. Reduced anxiety-like behavior and central neurochemical change in germ-free mice. Neurogastroenterol Motil. 2011;23:255–e119.

28. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab. 2010;7:30.

29. Schoderbeck M, Auer B, Legenstein E, Genger H, Sevelda P, Salzer H, März R, Lohninger A. Pregnancy-related changes of carnitine and acylcarnitine concentrations of plasma and erythrocytes. J Perinat Med. 1995;23:477-85.

30. Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Diseases. 2012;7:68.

31. Lohninger A, Karlic H, Lohninger S, Tammaa A, Jinniate S, Mascher H, Mascher D, Salzer H. Carnitine in pregnancy. Monatshefte für Chemie. 2005;136:1523-1533.

32. Schmidt-Sommerfeld E, Penn D, Wolf H. The influence of maternal fat metabolism on fetal carnitine levels. Early Human Develop. 1981;5:233-242.

33. Oey NA, van Vlies N, Wijburg FA, Wanders RJA, Attie-Bitach T, Vaz FM. L-Carnitine is synthesized in the human fetal–placental unit: potential roles in placental and fetal metabolism. Placenta. 2006;27:841-846.

34. Barrea L, Annunziata G, Muscogiuri G, Di Somma C, Laudisio D, Maisto M, De Alteriis G, Tenore GC, Colao A, Savastano S. Trimethylamine-N-oxide (TMAO) as novel potential biomarker of early predictors of metabolic syndrome. Nutrients. 2018;10:1971.
35. Schugar RC, Shih DM, Warrier M, Helsley RN, Burrows A, Ferguson D, Brown AL, Gromovsky AD, Heine M, Chatterjee A, Li L, Li XS, Wang Z, Willard B, Meng YH, Kim H, Che N, Pan C, Lee RG, Crooke RM, Graham MJ, Morton RE, Langefeld CD, Das SK, Rudel LL, Zein N, McCullough AJ, Dasarathy S, Tang WHW, Erokwu BO, Flask CA, Laakso M, Civelek M, Prasad SVN, Heeren J, Lusis AJ, Hazen SL, Brown JM. The TMAO-producing enzyme flavin-containing monooxygenase 3 regulates obesity and the beiging of white adipose tissue. Cell Rep. 2017;19:2451-2461.

36. Vinturache AE, Gyamf-Bannerman C, Hwang J, Mysorekar IU, Jacobsson B. Maternal microbiome – A pathway to preterm birth. Sem Fetal Neonat Med. 2016;21:94-99.

37. Witkin S. The vaginal microbiome, vaginal anti-microbial defence mechanisms and the clinical challenge of reducing infection-related preterm birth. BJOG. 2015;122:213-218.

38. Slow S, Lever M, Chambers S, George P. Plasma dependent and independent accumulation of betaine in male and female rat tissues. Physiol Res. 2009;58:403-10.

Table

Table 1. Baseline characteristics of spontaneous preterm birth cases and controls in a nested case-control study with in GBCS study.
| Characteristics                      | Cases (n=129) | Controls (n=258) | \( p \) |
|-------------------------------------|--------------|-----------------|------|
|                                     | n (%) or mean ± SD | n (%) or mean ± SD |     |
| Age (years)                         | 28.5±5.5     | 28.3±5.0        | 0.69 |
| Ethnic, n (%)                       |              |                 | 0.93 |
| Han                                 | 103 (79.8)   | 205 (79.5)      |     |
| other                               | 26 (20.2)    | 53 (20.5)       |     |
| Pre-pregnancy BMI, n (%)            |              |                 | 0.02 |
| Underweight (<18.5)                 | 34 (26.6)    | 59 (23.0)       |     |
| Normal (18.5-23.9)                  | 73 (57.0)    | 178 (69.3)      |     |
| Overweight (≥24)                    | 21 (16.4)    | 20 (7.8)        |     |
| Unclear                             | 1            | 1               |     |
| Family income, n (%)                |              |                 | 0.48 |
| <50,000 (¥)                         | 56 (43.4)    | 123 (47.7)      |     |
| ≥50,000 (¥)                         | 50 (38.8)    | 84 (32.6)       |     |
| Unclear                             | 23 (17.8)    | 51 (19.8)       |     |
| Education, n (%)                    |              |                 | 0.12 |
| High school or less                 | 81 (62.8)    | 182 (70.5)      |     |
| College or more                     | 48 (37.2)    | 76 (29.5)       |     |
| Drinking, n (%)                     |              |                 | 0.68 |
| Yes                                 | 30 (23.3)    | 65 (25.2)       |     |
| No                                  | 99 (76.7)    | 193 (74.8)      |     |
| Smoking, n (%)                      |              |                 | 0.22 |
| Yes                                 | 2 (1.6)      | 1 (0.4)         |     |
| No                                  | 127 (98.4)   | 257 (99.6)      |     |
| Gestational age at sample collection, n (%) |      |                 | 1.00 |
| ≤13 weeks                           | 46 (35.7)    | 93 (36.0)       |     |
| 14-27 weeks                         | 74 (57.4)    | 147 (57.0)      |     |
| ≥28 weeks                           | 9 (7.0)      | 18 (7.0)        |     |
| Preterm birth                       |              |                 |     |
| < 34 weeks                          | 29 (22.5)    |                 |     |
| ≥34 weeks                           | 100 (77.5)   |                 |     |
| Gravid, n (%)                       |              |                 | 0.79 |
| Primigravid                         | 39 (29.7)    | 80 (31.0)       |     |
| Multigravid                         | 90 (70.3)    | 178 (69.0)      |     |
| Parity, n (%)                       |              |                 | 0.61 |
| Primiparity                         | 79 (61.2)    | 151 (58.5)      |     |
| Multiparity                         | 50 (38.8)    | 107 (41.5)      |     |
| sPTB subtype ², n (%)               |              |                 |     |
| PPROM ³                             | 56 (43.4)    |                 |     |
| Preterm labor                       | 63 (48.8)    |                 |     |
| Missing                             | 10 (7.8)     |                 |     |
| Infant gender, n (%)                |              |                 | 1.00 |
| Male                                | 72 (55.8)    | 144 (55.8)      |     |
| Female                              | 57 (44.2)    | 114 (44.2)      |     |
| Infant weight (g)                   | 2362.2 ± 485.5 | 3223.3 ± 355.1 | < 0.001 |
| Infant height (cm)                  | 46.5 ± 3.4   | 50.4 ± 1.5      | < 0.001 |
| TMAO ⁴ (µmol/L)                     | 1.90 (1.84)  | 2.18 (1.87)     | 0.119 |
| L-carnitine (µmol/L)                | 24.29 (8.09) | 25.27 (10.11)   | 0.130 |
| Betaine (µmol/L)                    | 16.08 (8.39) | 16.69 (8.37)    | 0.574 |

GBCS, Guangxi Birth Cohort Study.

sPTB, spontaneous preterm birth.

PPROM, preterm prelabor rupture of membranes.
TMAO, Trimethylamine-N-Oxide.

Normally distributed variables were shown as mean ± SD and $P$ value was derived from t-test. Non-normally distributed variables were shown as median (IQR) and $P$ value was derived from U-test. Categorical variables were shown as numbers (percentage) and $P$ value was derived from Chi-square test.

**Figures**

Figure 1

Flow chart of the study population.
Figure 2

Associations between tertiles of serum TMAO, L-carnitine, and betaine levels and sPTB risk (A); stratified analyses by pre-pregnancy BMI: Individuals with BMI < 18.5 kg/m² (B), Individuals with 18.5 ≤ BMI ≤ 23.9 kg/m² (C), Individuals with BMI ≥ 24 kg/m² (D); stratified analyses by preterm prelabor rupture of membranes (PPROM): Individuals with PPROM (E), Individuals with preterm labor (F). Computed using conditional logistic regression modeling, adjusting for age, pre-pregnancy BMI (not for BMI stratified model), ethnic, education, smoking, and drinking.
Figure 3

The restricted cubic spline for the association between maternal serum TMAO and sPTB in different models. The lines represent adjusted odds ratios based on restricted cubic splines for the levels of serum TMAO in the logistic regression model. (A) All individuals. (B) Individuals with $18.5 \leq \text{BMI} \leq 23.9$ kg/m². (C) Individuals with preterm labor.